BAERVELDT Glaucoma Implants

BAERVELDT Glaucoma Implants

Easing the Pressure

The BAERVELDT BG 103-250, BAERVELDT BG 101-350 and BAERVELDT Pars Plana BG 102-350 Glaucoma Implants

Provide pressure control with a minimally invasive BAERVELDT Glaucoma Implant. Its fenestration system is designed to control bleb height and volume while a patented larger surface area enhances IOP control.1,2 When traditional glaucoma therapy can’t help the rising IOP, provide control with a BAERVELDT Glaucoma Implant.

BAERVELDT Glaucoma Implants

Easing the Pressure

The BAERVELDT BG 103-250, BAERVELDT BG 101-350 and BAERVELDT Pars Plana BG 102-350 Glaucoma Implants

Provide pressure control with a minimally invasive BAERVELDT Glaucoma Implant. Its fenestration system is designed to control bleb height and volume while a patented larger surface area enhances IOP control.1,2 When traditional glaucoma therapy can’t help the rising IOP, provide control with a BAERVELDT Glaucoma Implant.

Key Features

Glaucoma Control

Large plate implants facilitate aqueous outflow to help control IOP.3

Minimally Invasive

Only require single-quadrant insertion for better IOP control.4,5

Additional product benefits

Glaucoma Control

  • Allows improved aqueous filtration
  • Maximizes pressure relief

Minimally Invasive

  • The BAEVELDT Implants' patented bleb control mechanism allows fibrotic tissue growth through the fenestrations in the plate, controlling bleb height and volume.2,6
  • Minimizes the likelihood of ocular motility disturbances5
  • Helps ensure a low profile for better globe fit

Specifications

BAERVELDT BG 103-250 Glaucoma ImplantBAERVELDT BG 101-350 Glaucoma ImplantBAERVELDT Pars Plana BG 102-350 Glaucoma Implant

Surface Area:

250 mm2

350 mm2

350 mm2

Plate Length:

22 mm

32 mm

32 mm

Tube Length:

32 mm

32 mm

7 mm

Fenestrations:

4

4

4

Placement:

Anterior chamber

Anterior chamber

Posterior chamber (Pars Plana)

Drainage Mechanism:

Open tube

Open tube

Open tube with Hoffman Elbow

Learn More

Get the latest news and product info from Johnson & Johnson Vision.

Required fields are marked with an asterisk *

*

*

*

*

Your Role

*

*

Area of Interest

*

Cataract Surgery

OS Disease

LASIK Surgery

Send me updates and helpful resources via email

*

With your consent, we will use your information to send you information about our products and services tailored to your interests through email. You may withdraw your consent at any time.

Please read our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REFERENCES
1. Gedde S, Schiff man J, Feuer W, et al. Treatment outcomes in the tube versus trabeculectomy study after one year of follow- up. Am J Ophthalmol.2007;143(1):9-22.
2. Lloyd MA, Baerveldt G, Fellenbaum PS, et al. Intermediate- term results of a randomized clinical trial of the 350 - versus the 500 mm2 Baerveldt Implant. Ophthalmology. 1994;101(8):1456-1464.
3. Gedde, S. et al. Treatment outcomes in the tube versus trabeculectomy (TVT) study after fi ve years of follow- up. Am J Ophthalmol. 2012;153(5).
4. Heuer DK, Lloyd MA, Abrams DA, et al. Which is better? One or two? A randomized clinical trial of single- plate versus double- plate Molteno implantation for glaucomas in aphakia and pseudophakia. Ophthalmology. 1992;99(10):1512-1519.
5. Fellenbaum PS, Sidoti P, Heuer DK, Minckler DS, Baerveldt G, Lee PP. Experience with the Baerveldt implant in young patients with complicated glaucomas. J Glaucoma. 1995;4(2):91-97.
6. Hodkin MJ, Goldblatt WS, Burgoyne CF, Ball SF, Insler MS. Early clinical experience with the Baerveldt implant in complicated glaucomas. Am J Ophthalmol. 1995(1);120:32.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR BAERVELDT GLAUCOMA IMPLANTS
Rx Only

INDICATIONS
For use in patients (with prior vitrectomy for Pars Plana) with medically uncontrollable glaucoma and poor surgical prognosis, such as, but not limited to: neovascular glaucoma, aphakic/pseudophakic glaucomas, patients who have failed conventional surgery, congenital glaucomas and secondary glaucomas due to uveitis, epithelial downgrowth, etc.

CONTRAINDICATIONS
Bacterial conjunctivitis, bacterial corneal ulcers, endophthalmitis, orbital cellulitis, bacteremia or septicemia, active scleritis and/or no light perception.

WARNINGS
Do not use the device if sterile package integrity has been compromised. Do not resterilize the implant by any method. Do not reuse the implant. Do not store at temperatures above 45°C (113°F). Johnson & Johnson Surgical Vision single- use medical devices are labeled with instructions for use and handling to minimize exposure to conditions which may compromise the product, patient, or the user. The reuse of/resterilization/reprocessing of single- use Johnson & Johnson Surgical Vision, Inc. medical devices may result in physical damage to the medical device, failure of the medical device to perform as intended, and patient illness or injury due to infection, infl ammation, and/or illness due to product contamination, transmission of infection, and lack of product sterility. JJSV single- use medical devices are labeled with instructions for use and handling to minimize exposure to conditions which may compromise the product, patient, or the user.

COMPLICATIONS/ADVERSE EVENTS
The complications during and after surgery include, but are not limited to: chorodial hemorrhage, hyphema, serous choroidal eff usion, hypotony, fl at anterior chamber, phthisis bulbi, retinal detachment, endophthalmitis, tube erosion, tube touch to cornea, tube block by iris or vitreous, bullous keratopathy, uveitis and diplopia.

ATTENTION
Reference the labeling for a complete listing of Indications and Important Safety Information.

PP2023OTH5520

Johnson & Johnson MedTech

We support the AdvaMed Code of Ethics on interacting with Healthcare Professionals.

Advamed Logo

© Johnson & Johnson Vision Care, Inc. and Johnson & Johnson Surgical Vision, Inc. 2024 All rights reserved. This site is published by Johnson & Johnson Vision Care, Inc. and Johnson & Johnson Surgical Vision, Inc., which are solely responsible for its content.

Third party trademarks used herein are trademarks of their respective owners.

Vision Made Possible